Labs / CDMO: development & manufacturing
Amyl Tx
Liège, Belgium · amyltx.com
Amyl Therapeutics is a preclinical-stage biotechnology company in Liège, Belgium. It develops Pan-Amyloid Immunotherapy for amyloid-mediated neurodegenerative diseases such as Alzheimer’s and Parkinson’s, and for systemic amyloidosis.
They take quote requests by email.
What they offer
Pan-Amyloid Immunotherapy development
Develops therapeutic candidates designed to selectively target a common structural conformation shared across amyloid aggregates.
Amyloid aggregate clearance
Works on clearing toxic amyloid aggregates in later stages of disease.
Amyloid formation inhibition
Designs candidates to inhibit the formation of amyloid aggregates in earlier disease stages.
Neurodegenerative disease therapeutic research
Advances a universal approach aimed at treating amyloid-mediated neurodegenerative diseases.
What they work on
- Modalities
- Antibody
- Therapeutic areas
- neurodegenerative diseases, Alzheimer’s disease, Parkinson’s disease, systemic amyloidosis, amyloid-mediated diseases
- Sites
- Liège, Belgium
- Founded
- 2020
Similar labs. 3C Therapeutics, Adragos Pharma, AGC Biologics, Alphalyse
Found in a contract services directory. Listing built from amyltx.com. Work here? Claim this listing.